

21 March 2023

## **Resignation of Genetic Signatures Chief Financial Officer and Company Secretary**

Genetic Signatures [**ASX:GSS**, “**Company**”], a company focused on the development and commercialisation of its proprietary **3base**® platform technology, advises that Mr. Peter Manley has resigned from his role as Chief Financial Officer (CFO) and Company Secretary, as he transitions to semi-retirement. The Company has appointed Mr. Anthony Rule as interim CFO and Company Secretary with effect from 27<sup>th</sup> March, 2023 and has commenced an executive search process for a permanent replacement.

Mr. Manley joined GSS in October 2018 and provided financial oversight through the 2019 capital raise and during the COVID-19 pandemic, during which time the Company experienced rapid growth in Australia and abroad.

“I would like to sincerely thank Peter for his contributions over the last 4.5 years” says Chief Executive, Dr John Melki. “Peter has played an important role across our business during a period of rapid workforce expansion and revenue growth, and I wish him every success in his future endeavours.”

Chairman, Dr. Nick Samaras said, “On behalf of the Board, I would like to thank Peter for his financial leadership and also the oversight he provided through the significant periods of growth and development we have experienced.”

Mr. Rule has substantial experience in ASX listed companies, gained from companies such as Contango Asset Management Limited and Hunter Hall International. Mr. Manley will stay in the business for as long as necessary to ensure a smooth handover and transition occurs.

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Dr John Melki**

**Chief Executive Officer**

[john.melki@geneticsignatures.com](mailto:john.melki@geneticsignatures.com)

T: +61 (0)2 9870 7580

**Approved for release by Board of Directors**

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base**®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen*™ brand. Genetic Signatures’ proprietary MDx **3base**® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.